Nanologica to attend BIO-Europe Nov. 11-13 in Hamburg for partnering discussions

Nanologica will be attending BIO-Europe in Hamburg, Nov. 11-13, to meet with potential pharmaceutical partners regarding co-development and licensing of NIC-001, Nanologica’s drug candidate for treating gastroparesis, as well as seeking partnership for further drug delivery applications using NLAB Silica™.

Nanologica’s drug delivery platform NLAB Silica™ consists of nanoporous amorphous proprietary silica particles. By loading the API in NLAB Silica™ particles, Nanologica can overcome several of the challenges that prevent or limit effective treatment of many serious diseases. Some of the benefits of using NLAB Silica™ includes improving solubility, enhancing bioavailability and protecting APIs from degradation.

Nanologica is currently involved in several clinical trials, with its own asset NIC-001 which is a drug candidate in phase II for the treatment of gastroparesis, as well as in collaboration projects with large and mid-size pharma.

NIC-001 is a reformulation of metoclopramide for sublingual administration. Metoclopramide is a substance used to treat nausea and vomiting, and is the only drug approved by the FDA for the treatment of gastroparesis. The efficacy of existing metoclopramide-based drugs varies however widely, and the drugs are ineffective for many patients. The purpose of NIC-001 is to address these issues by bypassing the impaired gastrointestinal tract. The expected advantage of NIC-001 is a faster and more consistent symptom relief, and increased comfort for patients.

Gastroparesis (delayed emptying of the stomach) is a condition affecting many patients with diabetes. The symptoms consist for example of pain, nausea and vomiting. The medical need is large as the treatment options for affected patients are few. In the US approximately 2.3 million patients seek medical help for gastroparesis. About 2 million of these are women, whereof approximately half do not respond to available treatment options.

Nanologica is interested in partnering with pharma companies within the gastrointestinal area regarding NIC-001 and is also seeking partnership for further drug delivery applications using NLAB Silica™.

For inhalation, Nanologica produces spherical particles in the size range of 2 μm to 5 μm with narrow particle size distribution to reach the desired target site in the lung. The particles are non-aggregating, carry a high drug load, and offer a controlled and sustained release profile. The particles are soluble in simulated lung fluid.

To schedule a meeting, please do so via BIO-Europe’s online partnering platform at: www.partneringone.com, or contact:

Kia Bengtsson, Director Drug Development Nanologica

Ph: +46 70 144 36 30 or e-mail: kia.bengtsson@nanologica.com 

For technical information on Nanologica’s drug delivery platform, please contact:

Prof. Adam Feiler, CTO Nanologica AB

phone: +46 72 353 66 30 or e-mail adam.feiler@nanologica.com

For further information, please contact:

Andreas Bhagwani, CEO Nanologica AB
phone: +46 70 316 17 02 or e-mail: andreas.bhagwani@nanologica.com 

About Nanologica AB (publ)
Nanologica was founded in 2004 and is a nanotechnology company developing nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size and type of porosity of silica particles. This knowledge is applied within drug development and chromatography (a separation technique used in drug development and drug production). The company’s mission is to contribute to better and cheaper treatments for patients worldwide through the technology platform NLAB Silica™. Nanologica’s stock (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.

Tel: +46 70 316 17 02 eller e-post: andreas.bhagwani@nanologica.com